Skip to main content

Table 3 Univariate and multivariate analysis for overall survival

From: Perineural invasion as a prognostic factor for intrahepatic cholangiocarcinoma after curative resection and a potential indication for postoperative chemotherapy: a retrospective cohort study

Variable

Reference

Univariate COX regression

Multivariate COX regression

HR (95% CI)

P

HR (95% CI)

P

Age

< 60

0.861 (0.555, 1.335)

0.503

  

Gender

Female

0.709 (0.461, 1.091)

0.118

  

Location

Hilar

1.138 (0.648, 1.996)

0.653

  

HBsAg

Negative

0.817 (0.508, 1.315)

0.406

  

Tumor size (cm)

≤5

1.798 (1.135, 2.849)

0.012

0.115

Multiple tumor

No

1.804 (1.136, 2.867)

0.012

0.551

Vascular invasion

Negative

1.297 (0.838, 2.006)

0.243

  

Perineural invasion

Negative

2.515 (1.592, 3.975)

0.000

1.747 (1.080, 2.826)

0.023

Capsular invasion

Negative

1.391 (0.905, 2.140)

0.133

  

Visceral invasion

Negative

1.646 (0.971, 2.790)

0.064

0.718

AJCC T stage

T1 and T2

1.332 (0.865, 2.050)

0.193

  

AJCC N stage

N0 and Nx

2.805 (1.717, 4.585)

0.000

0.331

AJCC stage

I

    

 Stage II

 

4.876(2.239, 10.617)

0.000

3.307 (1.466, 7.460)

0.004

 Stage III

 

3.473 (1.814, 6.647)

0.000

2.799 (1.444, 5.424)

0.002

Tumor differentiation

Well to moderate

1.923 (1.179, 3.139)

0.009

2.179 (1.309, 3.626)

0.003

Liver cirrhosis

Negative

1.297 (0.837, 2.011)

0.245

  

ALT (U/L)

≤40

1.272 (0.816, 1.982)

0.289

  

AST (U/L)

≤40

1.463 (0.942, 2.274)

0.091

1.612 (1.003, 2.590)

0.049

PLT (×10^9/L)

≤300

1.834 (1.122, 2.997)

0.016

0.156

CEA (ng/ml)

≤5

1.936 (1.213, 3.092)

0.006

0.114

CA19–9 (U/ml)

≤200

3.220 (2.057, 5.042)

0.000

2.911 (1.798, 4.712)

0.000

CA24–2 (U/ml)

≤20

2.427 (1.554, 3.790)

0.000

0.983

Child-Pugh classification

A

1.355 (0.762, 2.411)

0.301

  

Postoperative chemotherapy

No

0.180 (0.057, 0.573)

0.004

0.174 (0.054, 0.566)

0.004

Post-recurrence anti-tumor therapy

No

0.871 (0.557, 1.361)

0.543

  
  1. HR hazard ratio, CI confidence interval, PNI perineural invasion, HBsAg hepatitis B surface antigen, AJCC American Joint Committee on Cancer, ALT Alanine aminotransferase, AST Aspartate aminotransferase, PLT Blood platelet, CEA Carcinoembryonic antigen